ClinicalTrials.gg
Not yet recruitingNCT07661797Updated Jun 22, 2026

Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4) in Patients With Advanced Solid Tumors, sponsored by Shandong New Time Pharmaceutical Co., LTD. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Shandong New Time Pharmaceutical Co., LTD (part of Lunan Pharmaceutical Group) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
294
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.

02

Conditions studied

  • Patients With Advanced Solid Tumors
03

In context

Lead sponsor

Shandong New Time Pharmaceutical Co., LTD is the lead sponsor of 35 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥18 years.
  2. Patients with advanced solid tumors (including but not limited to urothelial carcinoma, breast cancer, non-small cell lung cancer, ovarian cancer, endometrial cancer, and cervical cancer) that have been or cytologically confirmed as having failed/cannot tolerate/have no standard treatment/are currently unsuitable for standard treatment.
  3. Able to provide previous Nectin-4 expression testing results or preserved/fresh tumor tissue for Nectin-4 expression testing.
  4. At least one (CT or MRI long axis ≥ 10 mm, lymph node short axis ≥ 15 mm) according to v1.1 criteria. For lesions previously treated with radiotherapy, they will only be included as measurable lesions if there has been clear disease progression after radiotherapy.
  5. The function of vital organs must meet the following requirements (no blood components or cytokines may be used within 14 days prior to the first dose).

7) score 0-1. 8) Expected survival ≥ 3 months. 9) Willing to participate and sign form, and willing to follow the trial treatment protocol and visitation plan.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with an antibody-drug conjugate (ADC) exhibiting one of the following characteristics: payload as a topoisomerase I inhibitor (TOP 1 inhibitor); antibody target as Nectin-4.
  2. Received any P-glycoprotein (P-gp) inducer/inhibitor, strong inhibitor, or breast cancer resistance protein (BCRP) inhibitor within 14 days prior to first administration (see Appendix 3 for the exclusion list).
  3. Patients who received chemotherapy within 3 weeks or radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor treatments within 4 weeks prior to first administration of the study drug, excluding the following.
  4. Patients who received systemic therapy or any other form of therapy (equivalent to a prednisone dose >10 mg/day) within 2 weeks prior to the first dose.
  5. Patients whose adverse reactions to previous antitumor therapy have not recovered to a 5.0 grade ≤1 or the level specified in the inclusion/exclusion criteria (excluding toxicities deemed safe by the investigator, such as alopecia, grade 2 peripheral neurotoxicity, and stable hypothyroidism after hormone replacement therapy).
  6. Patients with primary central nervous system (CNS) , that have failed local treatment, or carcinomatous meningitis; patients with asymptomatic brain metastases, or stable clinical symptoms such as neurological symptoms and who do not require corticosteroids or other treatments targeting brain metastases for ≥4 weeks may be enrolled.
  7. Patients with uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  8. Patients with known interstitial lung disease (ILD) or non-infectious pneumonia, currently symptomatic or requiring prior systemic glucocorticoid therapy, whose toxicity assessment or management is deemed by the investigator to potentially affect the treatment.
  9. Patients with a history of organ transplantation or bone marrow transplantation, or who received autologous stem cell transplantation within 3 months prior to the first dose.
  10. Patients who underwent major surgery within 4 weeks prior to the first dose or have not yet recovered from surgery.
  11. Patients with any of the following laboratory findings.
  12. Patients with uncontrolled or severe cardiovascular disease, including those who developed Class II or higher congestive heart failure, unstable angina, myocardial infarction, or other cardiovascular diseases within 6 months prior to the first dose; or those with uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg after treatment).
  13. Patients with active infections requiring intravenous anti-infective therapy or a history of the following conditions, including but not limited to active diseases, severe mental illness, severe endocrine disorders such as severe thyroid dysfunction.
  14. Patients with the following ocular diseases: a) active infection or corneal ulcer; b) history of corneal transplantation; c) expected contact lens wear during the study period; d) poorly controlled glaucoma; e) poorly controlled or progressive retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disease; f) or other currently existing ocular diseases that would affect the assessment of ocular toxicity after the trial intervention.
  15. (HbA1c) ≥ 8.0%.
  16. Suffering from severe and/or uncontrolled comorbidities, such as decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, active inflammatory bowel disease, gastrointestinal perforation, intestinal obstruction, or gastrointestinal bleeding.
  17. Having a bleeding tendency (e.g., abnormal coagulation function tests, as determined by the investigator, or clinically significant bleeding symptoms as assessed by the investigator).
  18. Having received any other clinical trial drug/device treatment within 4 weeks prior to the first dose.
  19. Having a history of drug abuse or alcoholism within 6 months prior to the first dose.
  20. Having a history of severe allergies, or a known history of allergy to macromolecular protein preparations/monoclonal antibodies, or to any component of the investigational drug.
  21. Having received a live or attenuated within 4 weeks prior to the first dose.
  22. Pregnant or breastfeeding women, female participants of childbearing age, or male participants whose partners are women of childbearing age who do not agree to use medically approved effective (such as an intrauterine device or condom) during the study period and for 6 months after the last study drug treatment.
  23. Individuals deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
294 participants (estimated)

Study arms

  • Experimental
    LNF2105

    The dosage was increased sequentially from 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.0 mg/kg, 3.0 mg/kg, to 4.5 mg/kg.

    Drug: LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)

Interventions

  • DrugLNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)

    The dosage of LNF2105 was increased sequentially from 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.0 mg/kg, 3.0 mg/kg, to 4.5 mg/kg.

06

What researchers measure

Primary outcomes

  1. To evaluate of Safety and Tolerability of LNF2105 in Patients with Advanced Solid Tumors

    Numbers of treatment emergent adverse events with severity determined using NCI CTCAE v6.0 after single or multiple doses of LNF2105.

    Time frame: Approximately 24months

  2. To confirm Dose Limiting Toxicities (DLT) and determine MTD and RP2D for LNF2105

    Occurrence of Dose Limiting Toxicities as defined in the protocol

    Time frame: 28 days

Secondary outcomes

  1. Maximum observed plasma concentration of LNF2105 (ADC), Total Antibody and Free Payload (Cmax)

    Maximum observed plasma concentration ofLNF2105 (ADC), Total Antibody and Free Payload after single and multiple doses

    Time frame: Approximately 24 months

  2. Time to reach Cmax of LNF2105 (ADC), Total Antibody and Free Payload (Tmax)

    The amount of time to reach Cmax after single and multiple dose administration of LNF2105 (ADC), Total Antibody and Free Payload

    Time frame: 24 month

  3. Total Area Under the plasma concentration-time curve of LNF2105 (ADC), Total Antibody and Free Payload (AUC)

    Area under the plasma concentration versus time curve after single and multiple dose administration of LNF2105 (ADC), Total Antibody and Free Payload

    Time frame: 24 month

  4. Minimum Plasma Concentration (Cmin) of LNF2105 (ADC), Total Antibody and Free Payload

    Minimum Plasma Concentration (Cmin) of of LNF2105 (ADC), Total Antibody and Free Payload after multiple doses

    Time frame: 24 month

  5. To evaluate the preliminary antitumor activity of LNF2105: Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Approximately 24months

  6. To evaluate the preliminary antitumor activity of LNF2105: Progression free survival (PFS)

    PFS per investigator assessed RECIST 1.1

    Time frame: Approximately 24months

  7. To evaluate the preliminary antitumor activity of LNF2105: Duration of response (DOR)

    Anti-tumor preliminary efficacy will be evaluated of LNF2105 in accordance with RECIST v1.1

    Time frame: Approximately 24months

  8. To evaluate the preliminary antitumor activity of LNF2105: Disease control rate (DCR)

    DCR per investigator assessed RECIST 1.1

    Time frame: Approximately 24months

  9. To evaluate the preliminary antitumor activity of LNF2105: Time to response (TTR)

    TTR per investigator assessed RECIST 1.1

    Time frame: Approximately 24months

  10. To evaluate the preliminary antitumor activity of LNF2105: Overall survival (OS)

    OS per investigator assessed RECIST 1.1

    Time frame: Approximately 24months

  11. To evaluate the immunogenicity of LNF2105

    To evaluate the levels of anti-drug antibody (ADA) generated by study participants. Confirmatory testing will be performed on ADA-positive samples; confirmed positive samples will undergo subsequent titer determination as appropriate.

    Time frame: Approximately 24months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Jun 22, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2028
CompletionEst.
Aug 2028
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07661797
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jun 22, 2026

Study contacts

Shaohong Yin
Contact
yinshaohong@lunan.com.cn
86-15265901803

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion